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Résumé en
anglais
OBJECTIVE—The clinical expression of maturity-onset diabetes of the young
(MODY)-3 is highly variable. This may be due to environmental and/or genetic
factors, including molecular characteristics of the hepatocyte nuclear factor 1-α
(HNF1A) gene mutation.
RESEARCH DESIGN AND METHODS—We analyzed the mutations identified in
356 unrelated MODY3 patients, including 118 novel mutations, and searched for
correlations between the genotype and age at diagnosis of diabetes.
RESULTS—Missense mutations prevailed in the dimerization and DNA-binding
domains (74%), while truncating mutations were predominant in the transactivation
domain (62%). The majority (83%) of the mutations were located in exons 1- 6, thus
affecting the three HNF1A isoforms. Age at diagnosis of diabetes was lower in
patients with truncating mutations than in those with missense mutations (18 vs. 22
years, P = 0.005). Missense mutations affecting the dimerization/DNA-binding
domains were associated with a lower age at diagnosis than those affecting the
transactivation domain (20 vs. 30 years, P = 10−4). Patients with missense
mutations affecting the three isoforms were younger at diagnosis than those with
missense mutations involving one or two isoforms (P = 0.03).
CONCLUSIONS—These data show that part of the variability of the clinical
expression in MODY3 patients may be explained by the type and the location of
HNF1A mutations. These findings should be considered in studies for the search of
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